Completed × NIH × Anemia, Refractory, with Excess of Blasts × Clear all Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
Phase 3 Completed
144 enrolled 8 charts
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase 2 Completed
68 enrolled 11 charts
Preventing Stem Cell Transplant Complications With a Blood Separator Machine
Phase 1/2 Completed
41 enrolled 21 charts
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
Phase 2 Completed
279 enrolled 28 charts
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
Phase 2 Completed
12 enrolled 11 charts
Stem Cell Transplantation for Patients With Cancers of the Blood
Phase 2 Completed
61 enrolled 6 charts
MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
Phase 2 Completed
24 enrolled 5 charts
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
Phase 2 Completed
23 enrolled 11 charts
Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes
Phase 1 Completed
24 enrolled
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
Phase 1/2 Completed
95 enrolled 5 charts
Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases
Phase 3 Completed
230 enrolled
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 3 Completed
2,000 enrolled
Tipifarnib in Treating Patients With Myelodysplastic Syndromes
Phase 1 Completed
65 enrolled
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia
Phase 3 Completed
2,000 enrolled
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase 2/3 Completed
2,000 enrolled
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
Phase 1 Completed
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
Phase 1 Completed
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
Phase 1 Completed
Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation
Phase 2/3 Completed
Decitabine in Treating Patients With Myelodysplastic Syndrome
Phase 2 Completed
75 enrolled
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
Phase 1/2 Completed
Bevacizumab in Treating Patients With Myelodysplastic Syndrome
Phase 1/2 Completed
Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia
Phase 1 Completed
24 enrolled
Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease
Phase NA Completed
30 enrolled
Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer
Phase 2 Completed
52 enrolled
Tipifarnib in Treating Patients With Advanced Hematologic Cancer
Phase 1 Completed
36 enrolled
XK469R in Treating Patients With Refractory Hematologic Cancer
Phase 1 Completed
60 enrolled
Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome
Phase 1/2 Completed
26 enrolled
Thalidomide in Treating Patients With Myelodysplastic Syndrome
Phase 2 Completed
29 enrolled
PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome
Phase 1 Completed
30 enrolled
Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy
Phase 1/2 Completed
37 enrolled
BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia
Phase 1 Completed
30 enrolled
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
Phase 2 Completed
74 enrolled
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
Phase 1 Completed
40 enrolled
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Phase 3 Completed
880 enrolled
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
Phase 1 Completed
40 enrolled
Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Phase 1/2 Completed
69 enrolled
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
Phase 1 Completed
20 enrolled
FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma
Phase 2 Completed
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 3 Completed